Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript

Dennis McGrath: Yes, that’s a great question. That comes up a lot. I think I might have mentioned this on previous calls. We have previously done an analysis in Europe. The EsoCheck has CE mark, and we have the ability to run the assay there. Europe is very tough for molecular diagnostic screening tests, some of the genetic profiling tests and so forth that have a strong presence there. But even test like Cologuard and others have struggled in Europe because the overall reimbursements there are low. We’ve had some discussions about Canada, and that’s really been our focus at this point. So we get occasional input from other parts of the world, but that’s not been a major focus right now. We’re really laser focused on the U.S. market.

Operator: This concludes our question-and-answer session. I would like to turn the conference over to Dr. Aklog for any closing remarks.

Dr. Lishan Aklog: Great. Thanks, operator, and thank you all for your attention this morning, and thanks for all the great questions. It’s always enjoyable to discuss the results. As I said, we couldn’t be happier with this quarter. It’s really as a result of incredibly hard work that’s laid the groundwork on clinical research on our laboratory and market access team and so forth, and we’re looking forward to a bright future for Lucid technologies. We look forward to you continuing to update you on our progress through press releases and follow-up calls. And as always, feel free to contact us through mikeparks@met@pavmed.com and to follow us some social media. So thank you all, and have a great day.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.